Analysts Turn Bullish On Gilead After Q3 Earnings Surpass Expectations
Thursday, Gilead Sciences Inc (NASDAQ:GILD) reported Q3 revenue decreased 5% Y/Y to $7.04 billion, which beat average analyst estimates of $6.12…
Where Gilead Sciences Stands With Analysts
Over the past 3 months, 8 analysts have published their opinion on Gilead Sciences (NASDAQ:GILD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Wells Fargo Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $75
Wells Fargo analyst Mohit Bansal maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and raises the price target from $74 to $75.
Truist Securities Upgrades Gilead Sciences to Buy, Raises Price Target to $91
Truist Securities analyst Robyn Karnauskas upgrades Gilead Sciences (NASDAQ:GILD) from Hold to Buy and raises the price target from $76 to $91.
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell
• Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
Here’s How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.45% on an annualized basis producing an average annual return of 14.87%. Currently, Gilead Sciences has a market capitalization of $84.95 billion.
Kite’s Yescarta First CAR T-cell Therapy To Receive European Marketing Authorization For Use In Second-Line Diffuse Large B-Cell Lymphoma And High-Grade B-Cell Lymphoma
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (NASDAQ:GILD), today announces that the European Commission (EC) has granted approval for the use of Yescarta® (axicabtagene ciloleucel) for the
Gilead And MacroGenics Announce Oncology Collaboration To Develop Bispecific Antibodies; Gilead Will Pay Macrogenics An Upfront Payment Of $60M And MacroGenics Will Be Eligible To Receive Up To $1.7B In Potential Milestones
Gilead Sciences, Inc. (NASDAQ:GILD) and MacroGenics (NASDAQ:MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using